Silk Road Medical Inc (SILK, Financial), a company specializing in medical devices for the treatment of carotid artery disease, has reported an insider purchase by Director Kevin Ballinger. According to a recent SEC filing, the insider acquired 11,700 shares of the company on March 5, 2024.
Over the past year, the insider's transaction history indicates that Kevin Ballinger has purchased a total of 11,700 shares and has not sold any shares of Silk Road Medical Inc. This latest transaction reflects a continued confidence in the company's prospects from the insider's perspective.
The insider transaction history for Silk Road Medical Inc shows a pattern of insider activity. In the past year, there has been a total of 1 insider buy and 20 insider sells. This trend can provide an indication of the insider sentiment towards the stock's potential performance.
On the valuation front, Silk Road Medical Inc shares were trading at $16.99 on the day of the insider's purchase, resulting in a market capitalization of $613.475 million. When compared to the GuruFocus Value (GF Value) of $61.04, the price-to-GF-Value ratio stands at 0.28, suggesting that the stock may be categorized as a Possible Value Trap, Think Twice according to its GF Value.
The GF Value is a proprietary intrinsic value estimate used by GuruFocus. It is derived from historical trading multiples such as the price-earnings ratio, price-sales ratio, price-book ratio, and price-to-free cash flow, along with a GuruFocus adjustment factor based on the company's historical returns and growth, and future business performance estimates provided by Morningstar analysts.
Silk Road Medical Inc's business focuses on the development of medical devices designed to prevent strokes by treating carotid artery disease through minimally invasive procedures. The company's commitment to innovation in this field is reflected in its product offerings and ongoing research and development efforts.
This article, generated by GuruFocus, is designed to provide general insights and is not tailored financial advice. Our commentary is rooted in historical data and analyst projections, utilizing an impartial methodology, and is not intended to serve as specific investment guidance. It does not formulate a recommendation to purchase or divest any stock and does not consider individual investment objectives or financial circumstances. Our objective is to deliver long-term, fundamental data-driven analysis. Be aware that our analysis might not incorporate the most recent, price-sensitive company announcements or qualitative information. GuruFocus holds no position in the stocks mentioned herein.
